Latest News by Industry
![Denali Therapeutics Inc. [DNLI] reports annual net loss of $145,224,000.0](/_next/image?url=https%3A%2F%2F10kinfo-appdata.s3.us-west-2.amazonaws.com%2Fedgar0105%2FCompanyLogos%2FUS%2FDNLI.png&w=1200&q=75)
Denali Therapeutics Inc. [DNLI] has reported a net loss of $145,224,000.0 for year ended Dec 31, 2023.
The Company said in a filing before the Securities and Exchange Commission that its total revenue for the year was $330.5 million
Based in SOUTH SAN FRANCISCO, California, Denali Therapeutics Inc. operates in the MANUFACTURING sector.
In the Consolidated Statements of Operations and Comprehensive Loss, the annual financial results for the years ended December 31, 2023, December 31, 2022, and December 31, 2021, were compared as follows:
- Collaboration revenue for the year ended December 31, 2023, amounted to $330.5 million, significantly higher compared to $108.5 million in the previous year and $48.7 million in 2021.
- Operating expenses reported for the same period reflected a total of $527.2 million, an increase from $449.2 million in the prior year and $344.4 million in 2021. Research and development expenses were $423.9 million in 2023, up from $358.7 million in 2022.
- The loss from operations for 2023 was $196.7 million, an improvement from $340.7 million in 2022 and $295.8 million in 2021.
- Net loss for the year ended December 31, 2023, was $145.2 million, showing a decrease from $326 million in 2022 and $290.6 million in 2021.
- In terms of earnings per share (EPS), the net loss per share for the year 2023, both basic and diluted, was reported at $1.06, compared to $2.60 in 2022 and $2.39 in 2021.
These financial figures demonstrate a positive trend in revenue growth, a decrease in net loss, and an improved loss from operations for the current reporting period compared to the previous year. The company's performance appears to be on a positive trajectory, with efforts to control operating expenses contributing to the overall improvement in financial results.
Also Read: